'Deck chairs on the Titanic'?: AMAG's CEO departure, drug dumps may not right the ship, analyst says
After forfeiting two board seats and undertaking a strategic review, AMAG Pharmaceuticals is saying goodbye to its CEO and two of its drugs. But with another med likely being pulled from the market, ...
Amid a proxy fight with activist investor Caligan Partners, AMAG Pharmaceuticals implored shareholders to stay the course on the drugmaker’s strategic vision. But with one of its drugs facing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback